Breast Cancer Screening
MedCognetics and AWS Partner to Bring AI-Powered Breast Cancer Screening to Underserved Indian Communities
MedCognetics collaborates with AWS and Health Within Reach Foundation to deploy AI-enabled mobile mammography units in India, aiming to reduce breast cancer disparities in underserved populations.
Izotropic Corporation Highlights Critical Need for Advanced Breast Imaging Technology During Awareness Month
Izotropic Corporation emphasizes the limitations of current breast cancer screening tools and the potential of its IzoView Breast CT Imaging System to address diagnostic challenges, particularly for women with dense breast tissue, as global breast cancer cases continue to rise.
New Jersey Law Firm Launches #EmployersThinkPink Initiative to Promote Breast Cancer Screening Through Paid Time Off
A New Jersey personal injury law firm has launched the #EmployersThinkPink initiative, encouraging companies nationwide to provide paid time off for mammograms, highlighting how corporate policies can significantly impact early breast cancer detection and employee health outcomes.
Izotropic Corporation Highlights AI's Transformative Role in Breast Imaging with New Technology Platform
Izotropic Corporation's new feature article emphasizes how its IzoView Breast CT Imaging System is positioned to revolutionize breast cancer screening through AI integration, addressing limitations of traditional mammography systems.
AI Mammography Platform Deployed in Rural India to Address Critical Radiologist Shortage
MedCognetics and AKARUI Solutions have partnered to deploy AI-powered mammography screening in mobile vans across rural India, addressing the severe shortage of breast imaging specialists and improving early cancer detection in underserved regions.
Izotropic's $500K Breast CT System Challenges $8.7B Imaging Market with Lower Costs and Superior Technology
Izotropic Corporation's IzoView Breast CT system offers 360-degree 3D imaging without compression at up to 67% lower cost than competitors, potentially transforming breast cancer screening for women with dense breast tissue and reducing the $8 billion annual burden of inconclusive results.